Trial Profile
Molecular, Genetic, and Genomic Assessments of MTOR Inhibition in Metastatic Hormone-Refractory Prostate Cancer Tissue From Patients Treated With RAD001.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Prostate cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 14 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Jun 2011 Planned end date changed from 1 Dec 2009 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 21 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.